Literature DB >> 7882168

HIV-1 Nef leads to inhibition or activation of T cells depending on its intracellular localization.

A S Baur1, E T Sawai, P Dazin, W J Fantl, C Cheng-Mayer, B M Peterlin.   

Abstract

Nef of primate lentiviruses is required for viremia and progression to AIDS in monkeys. Negative, positive, and no effects of Nef have also been reported on viral replication in cells. To reconcile these observations, we expressed a hybrid CD8-Nef protein in Jurkat cells. Two opposite phenotypes were found, which depended on the intracellular localization of Nef. Expressed in the cytoplasm or on the cell surface, the chimera inhibited or activated early signaling events from the T cell antigen receptor. Activated Jurkat cells died by apoptosis, and only cells with mutated nef genes expressing truncated Nefs survived, which rendered Nef nonfunctional. These mutations paralleled those in other viral strains passaged in vitro. Not only do these positional effects of Nef reconcile diverse phenotypes of Nef and suggest a role for its N-terminal myristylation, but they also explain effects of Nef in HIV infection and progression to AIDS.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7882168     DOI: 10.1016/1074-7613(94)90068-x

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  105 in total

1.  Mechanism for down-regulation of CD28 by Nef.

Authors:  T Swigut; N Shohdy; J Skowronski
Journal:  EMBO J       Date:  2001-04-02       Impact factor: 11.598

2.  Mutation of a conserved residue (D123) required for oligomerization of human immunodeficiency virus type 1 Nef protein abolishes interaction with human thioesterase and results in impairment of Nef biological functions.

Authors:  L X Liu; N Heveker; O T Fackler; S Arold; S Le Gall; K Janvier; B M Peterlin; C Dumas; O Schwartz; S Benichou; R Benarous
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  The Nef protein of HIV-1 associates with rafts and primes T cells for activation.

Authors:  J K Wang; E Kiyokawa; E Verdin; D Trono
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

4.  HIV-1 Nef impairs MHC class II antigen presentation and surface expression.

Authors:  P Stumptner-Cuvelette; S Morchoisne; M Dugast; S Le Gall; G Raposo; O Schwartz; P Benaroch
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-02       Impact factor: 11.205

5.  A role for natural simian immunodeficiency virus and human immunodeficiency virus type 1 nef alleles in lymphocyte activation.

Authors:  L Alexander; Z Du; M Rosenzweig; J U Jung; R C Desrosiers
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

6.  Nef enhances human immunodeficiency virus type 1 infectivity in the absence of matrix.

Authors:  Tatyana Dorfman; Elena Popova; Massimo Pizzato; Heinrich G Göttlinger
Journal:  J Virol       Date:  2002-07       Impact factor: 5.103

Review 7.  HIV-1 Nef control of cell signalling molecules: multiple strategies to promote virus replication.

Authors:  Alison L Greenway; Gavan Holloway; Dale A McPhee; Phoebe Ellis; Alyssa Cornall; Michael Lidman
Journal:  J Biosci       Date:  2003-04       Impact factor: 1.826

8.  Recent Insights into HIV Accessory Proteins.

Authors:  Jenny L. Anderson; Thomas J. Hope
Journal:  Curr Infect Dis Rep       Date:  2003-10       Impact factor: 3.725

9.  HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor.

Authors:  Maria A De Francesco; Manuela Baronio; Simona Fiorentini; Costantino Signorini; Carlo Bonfanti; Claudio Poiesi; Mikulas Popovic; Manuela Grassi; Emirena Garrafa; Luisa Bozzo; George K Lewis; Stefano Licenziati; Robert C Gallo; Arnaldo Caruso
Journal:  Proc Natl Acad Sci U S A       Date:  2002-07-08       Impact factor: 11.205

10.  Functional characterization of human immunodeficiency virus type 1 nef genes in patients with divergent rates of disease progression.

Authors:  N L Michael; G Chang; L A d'Arcy; C J Tseng; D L Birx; H W Sheppard
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.